investor.pumabiotechnology.com investor.pumabiotechnology.com

investor.pumabiotechnology.com

Puma Biotechnology Investor Center |

Puma Biotechnology, Inc is a development stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Puma Biotechnology was founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion.

http://investor.pumabiotechnology.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR INVESTOR.PUMABIOTECHNOLOGY.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

March

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Tuesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.7 out of 5 with 3 reviews
5 star
0
4 star
2
3 star
1
2 star
0
1 star
0

Hey there! Start your review of investor.pumabiotechnology.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

1.3 seconds

FAVICON PREVIEW

  • investor.pumabiotechnology.com

    16x16

CONTACTS AT INVESTOR.PUMABIOTECHNOLOGY.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Puma Biotechnology Investor Center | | investor.pumabiotechnology.com Reviews
<META>
DESCRIPTION
Puma Biotechnology, Inc is a development stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Puma Biotechnology was founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion.
<META>
KEYWORDS
1 news
2 investor
3 investor center
4 media
5 press
6 Biotechnology
7 development stage
8 biopharmaceutical
9 in-licensing
10 cancer treatment
CONTENT
Page content here
KEYWORDS ON
PAGE
stock information,featured press release,press releases,more press releases,search investor relations,enter your keywords,advanced search,investor resources,registration,media requests,email alerts,rss feeds,contacts,ir@pumabiotechnology com,legal notice
SERVER
Apache
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Puma Biotechnology Investor Center | | investor.pumabiotechnology.com Reviews

https://investor.pumabiotechnology.com

Puma Biotechnology, Inc is a development stage biopharmaceutical company dedicated to in-licensing and developing novel therapeutics for the treatment of cancer. Puma Biotechnology was founded by Alan H. Auerbach, who previously served as Founder, Chief Executive Officer and President of Cougar Biotechnology, Inc, a company dedicated to in-licensing and developing drugs for the treatment of cancer. Cougar was acquired by Johnson & Johnson in July 2009 for approximately $1 billion.

INTERNAL PAGES

investor.pumabiotechnology.com investor.pumabiotechnology.com
1

Annual Report/Proxy | Puma Biotechnology Investor Center

http://investor.pumabiotechnology.com/annual-reports

2016 Annual Meeting Notice. 2016 Annual Meeting Notice. 2016 Proxy Statement Amendment No. 1. 2016 Proxy Statement Amendment No. 1. 2015 Annual Meeting Notice. 2015 Annual Meeting Notice. Amendment to 2014 Proxy Statement. Amendment to 2014 Proxy Statement. 2013 Annual Meeting Notice. 2013 Annual Meeting Notice. 2012 Annual Meeting Notice. 2012 Annual Meeting Notice. Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150. Los Angeles, CA 90024. Puma Biotechnology, Inc. Privacy Policy.

2

Press Releases | Puma Biotechnology Investor Center

http://investor.pumabiotechnology.com/press-releases

Puma Biotechnology to Present at Credit Suisse Healthcare Conference. 10/31/16 1:15 pm PDT. Puma Biotechnology Closes $172 Million Public Offering of Common Stock. 10/25/16 8:45 am PDT. Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares. 10/21/16 5:31 am PDT. Puma Biotechnology Prices Public Offering of Common Stock. 10/19/16 8:18 pm PDT. Puma Biotechnology Announces Proposed Public Offering of Common Stock. 10/18/16 1:15 pm PDT. 9/20/16 5:01 am PDT.

3

Stock Information | Puma Biotechnology Investor Center

http://investor.pumabiotechnology.com/stock-information

Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150. Los Angeles, CA 90024. Puma Biotechnology, Inc. Privacy Policy.

4

Annual Meeting | Puma Biotechnology Investor Center

http://investor.pumabiotechnology.com/annual-meeting

2016 Annual Meeting Notice. 2016 Annual Meeting Notice. 2016 Proxy Statement Amendment No. 1. 2016 Proxy Statement Amendment No. 1. 2015 Annual Meeting Notice. 2015 Annual Meeting Notice. Amendment to 2014 Proxy Statement. Amendment to 2014 Proxy Statement. 2013 Annual Meeting Notice. 2013 Annual Meeting Notice. 2012 Annual Meeting Notice. 2012 Annual Meeting Notice. Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150. Los Angeles, CA 90024. Puma Biotechnology, Inc. Privacy Policy.

5

Investor FAQs | Puma Biotechnology Investor Center

http://investor.pumabiotechnology.com/faqs

1 What does Puma Biotechnology do? Puma is a development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of cancer. Puma focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. 2 When was Puma founded and where was it incorporated? 3 When did Puma become a public company? As of Febru...

UPGRADE TO PREMIUM TO VIEW 3 MORE

TOTAL PAGES IN THIS WEBSITE

8

LINKS TO THIS WEBSITE

pumabiotechnology.com pumabiotechnology.com

Puma Biotechnology

http://www.pumabiotechnology.com/about_overview.html

We focus on in-licensing innovative drug candidates that are undergoing or have already completed initial clinical testing for the treatment of various forms of cancer and then seek to further develop these drug candidates for commercial use. Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150. Los Angeles, CA 90024. 2016 Puma Biotechnology, Inc.

pumabiotechnology.com pumabiotechnology.com

Puma Biotechnology

http://www.pumabiotechnology.com/2015pr.html

Dec 30, 2015. Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card. Dec 29, 2015. Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card. Dec 23, 2015. Dec 18, 2015. Dec 16, 2015. Dec 11, 2015. Dec 10, 2015. Dec 10, 2015. Puma Biotechnology...

pumabiotechnology.com pumabiotechnology.com

Puma Biotechnology

http://www.pumabiotechnology.com/pipeline.html

Puma Biotechnology, Inc. 10880 Wilshire Blvd., Suite 2150. Los Angeles, CA 90024. 2016 Puma Biotechnology, Inc.

UPGRADE TO PREMIUM TO VIEW 1 MORE

TOTAL LINKS TO THIS WEBSITE

4

OTHER SITES

investor.prudential.com investor.prudential.com

Prudential Financial, Inc. - Investor Relations - Investor Relations

Skip to main content. 160;     Email This Page. 160;     RSS Feeds. 160;     Email Alerts. Prudential Financial, Inc. (NYSE: PRU), a financial services leader with more than $1 trillion of assets under management as of June 30, 2015, has operations in the United States, Asia, Europe, and Latin America. As of 08/07/15   4:00 pm ET. Last stock trade for PRU is. August 05, 2015. 2Q15 Quarterly Financial Supplement. April 06, 2015. Prudential Insurance 2014 Statutory Annual Statement Excerpts. Annual Report ...

investor.prudentialcapitalgroup.com investor.prudentialcapitalgroup.com

Investors | Prudential Capital Group

Prudential Private Placement Investors L.P. works with institutional clients to design and manage investment grade and high yield portfolios to meet clients’ objectives. Learn More ». Our fourth mezzanine fund, Prudential Capital Partners IV, L.P., closed with an initial commitment of $1.15 billion in 2012. Learn More ». PRIVEST, launched in 1976, is an investment grade commingled insurance company separate account and has grown to $5.6 billion as of 3/31/15. Learn More ». Learn More ». Our regional offi...

investor.pseg.com investor.pseg.com

PSEG Investor Relations |

Contact us : 800-436-7734. Gas leak / power outage. Interview and Test Preparation. Certificate of Employee Information Report. Calendar of Upcoming Events. Forward Looking Statements and GAAP Disclaimer. PSEG in the Community. Directions to PSEG Headquarters. PSEG as 100 People. Energy and Environmental Resource Center (EERC). PRESENTATIONS, WEBCASTS and MEETING MATERIALS. CALENDAR OF UPCOMING EVENTS. FORWARD LOOKING STATEMENT AND GAAP DISCLAIMER. PSEG ANNOUNCES 2017 RESULTS. Feb 28, 2018 - Newark, N&#4...

investor.psf.it investor.psf.it

Investor Relations - Poligrafica San Faustino

Investor Relations - Poligrafica S.Faustino SPA. Qualche anno fa, a proposito di una societa' americana che ha focalizzato la sua consulenza di comunicazione sul web, leggevo: Le societa' che gestiscono le loro relazioni interattive usano il web come strumento per chiudere il gap fra le loro promesse e le aspettative del cliente. Sono convinta che la capacita' di gestire sapientemente la comunicazione economico-finanziaria diventera' un fattore critico di successo aziendale. Credo che questo mi abbia...

investor.ptc.com investor.ptc.com

Investor Relations - PTC Inc.| PTC

Physical digital convergence has the power to transform your business. Let PTC show you how. PTC at the Paris Air Show 2017. PTC at the Paris Air Show 2017. Experience Why Defense and Commercial Airline Leaders Choose PTC. Discover Your New Augmented Reality. Discover Your New Augmented Reality. Master Design Reviews with Creo 4.0: M010. Forrester Research names PTC an IoT Software Platforms Leader. Forrester Research names PTC an IoT Software Platforms Leader. Annual Reports and Proxies. 097 ( 1.26%).

investor.pumabiotechnology.com investor.pumabiotechnology.com

Puma Biotechnology Investor Center |

8/10/15 1:07 pm PDT. Puma Biotechnology Reports Second Quarter 2015 Financial Results. LOS ANGELES- ( BUSINESS WIRE. 8/10/15 1:07 pm PDT. Puma Biotechnology Reports Second Quarter 2015 Financial Results. 6/4/15 1:05 pm PDT. Puma Biotechnology to Present at Goldman Sachs Healthcare Conference. 6/1/15 8:25 am PDT. Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival.

investor.purestorage.com investor.purestorage.com

Q4 Web Site Development

Q4 Web Maintenance Message. This site is currently under development and not yet available for public viewing. For more information on why this site is not available, please contact Q4.

investor.puricore.com investor.puricore.com

PuriCore » Investor Relations » Investor Home

Financials and Ownership Information. Annual and General Meetings. Contacts, Key Advisers and FAQs. Corporate Profile and Strategy. Change of Registered Office. There are currently no events scheduled. Privacy Policy and Cookies.

investor.qiwi.com investor.qiwi.com

QIWI Group - Investor Relations

View all ». Jun 30, 2015. QIWI Completes Acquisition of Contact and Rapida. Jun 29, 2015. QIWI International Merchants Division Will Be Strengthened by New Department Head, Dmitry Danilenko. View all ». May 22, 2015. May 14, 2015 at 8:30 AM ET. QIWI PLC First Quarter 2015 Financial Results.

investor.qlik.com investor.qlik.com

Qlik Investor Relations – Investor Relations

4:00 PM ET on Aug 14, 2015. Delayed at least 20 minutes. View all ». Aug 10, 2015. Austrian Manufacturing Giant Selects Qlik to Gain Better Insights into SAP Sales Data. Jul 27, 2015. Research Confirms Future of Supply Chain Analytics is Visual, Multi-Sourced, and Predictive. Phone: 1 484 685-0578. 150 N Radnor Chester Rd, Suite E220. Radnor, PA 19087. Fax: 1 484 313-3513. Log in to Qlik. Get a Qlik Account. Call 1 (888) 828-9768 (N. America). Directory of Worldwide Offices. Directory of Worldwide Offices.

investor.qrf.be investor.qrf.be

Homepage - EN | Qrf

Skip to main content. Coordinated Articles of Association (NL). Remuneration and Nomination Committee. Specific information on transactions. Qrf City Retail reaches agreement to acquire Schuttershofstraat 53 and. Wapper 14-16, Antwerp. Qrf - Presentation FY 2015 Results. Qrf - Annual results 2015. Stable and predictable cash flows. High pay-out ratio (more than 80%). Attractive gross dividend yield. High occupancy rate of 97.82. Real estate portfolio of 250 MEUR. Focus on inner-city locations.